EpiPen

Mylan NV (NASDAQ: MYL) CEO Heather Bresch told a U.S. congressional committee last week that the company makes a profit of around $100 for each package of EpiPen it sells. Bresch testified in front of the committee amid a scandal in which Mylan may have unjustifiably raised the price of its...

Mylan NV (NASDAQ: MYL)'s EpiPen controversy, in which the company may have been unjustified in raising the cost of its life saving device over the years, is far from over. Even though Mylan's CEO Heather Bresch sat in front of a U.S. House Oversight panel this week to defend the company's business...

Argus’ Jacob Kilstein believes generic drug companies would “continue to benefit from the increased focus on cost-effective healthcare.” Kilstein maintains a Buy rating and a $55 price target on Mylan NV (NASDAQ: MYL). Attractive Entry Point The stock has declined 17 percent over...

Bill George, a Harvard Business School senior fellow and ex-chairman of Medtronic PLC (NYSE: MDT) has some harsh words for Mylan NV (NASDAQ: MYL)'s CEO Heather Bresch. Speaking as a guest on CNBC's "Squawk On The Street" on Wednesday, George said that Bresch could be in for a "rough time" as she is...

Mylan NV (NASDAQ: MYL)'s CEO Heather Bresch could face the wrath of the U.S. Congress on Wednesday given the company's practice of boosting the price of its potential life-saving EpiPen. According to a Bloomberg report, Robert Coury, Bresch's boss, won't be taking the stand on Wednesday. Coury,...

Just two months away from Election Day, it is accurate and fair to say this presidential election year — as have previous ones — has been unkind to the healthcare sector. Election Year Blues The third-largest sector weight in the S&P 500 is lagging the benchmark U.S. equity index by...

Biopharmaceutical company MannKind Corporation (NASDAQ: MNKD) is "making progress" in developing a less costly alternative to Mylan NV (NASDAQ: MYL)'s EpiPen. According to Connecticut-based News Times, MannKind's local manufacturing facility employs around 150 people in the city and plays a key...

Mylan NV (NASDAQ: MYL) disclosed that its American unit would unveil the first generic to EpiPen Auto-Injector at a cost of $300 per two-pack carton. This represented a discount over 50 percent to its list price or wholesale acquisition cost of the branded medicine. The company clarified that...

It’s been a rough week for Mylan NV (NASDAQ: MYL). To stem the tide of criticism over price hikes of its EpiPen, CEO Heather Bresch went on CNBC Thursday to offer a "Savings Card" to consumers. That apparently was all Wall Street analysts needed to hear. Barclays said the...

Mylan NV (NASDAQ: MYL) has been making the wrong kind of headlines this week. Democratic presidential nominee Hillary Clinton singled out Mylan for its 400 percent increase in the price of EpiPens in recent years. “It’s wrong when drug companies put profits ahead of patients, raising...

Mylan NV (NASDAQ: MYL) has received overwhelming criticism, even inciting mention from Hillary Clinton, for increasing the price of its life-saving EpiPen product 400 percent while raising the Mylan CEO’s salary by 600 percent. Company shares have begun to rebound Thursday, however, due to...

Mylan NV (NASDAQ: MYL)'s announcement that it will offer patient assistance via a coupon that could effectively slash the price of its EpiPen drug by 50 percent should "quell" investor concern, at least according to Goldman Sachs' Jami Rubin. Rubin commented in a report that...

Mylan NV (NASDAQ: MYL), the seller of a potentially life-saving medical device called EpiPen, saw its share of controversy this week when officials of the U.S. government called into question the company's pricing policies. In 2008, the EpiPen sold for around $100 but has since risen six...

Mylan NV (NASDAQ: MYL)'s 400 percent price hike to a potentially life-saving device was called into question by members of the U.S. government this week. Mylan, the maker of EpiPen, an epinephrine auto injector used in emergency cases by individuals suffering a severe allergic reaction,...

Just about a year after Democratic presidential nominee sent biotechnology stocks and exchange traded funds tumbling with rhetoric aimed at high drug prices, one would think that any healthcare company and its executives opting to raise prices on devices, pharmaceuticals and treatments by...